Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus PULMICORT FLEXHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus PULMICORT FLEXHALER.
FLUTICASONE PROPIONATE vs PULMICORT FLEXHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; binds to cytosolic glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins, leukotrienes) and suppression of immune cell activity.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
Inhalation: 88-440 mcg twice daily for asthma (DPI: 100-500 mcg twice daily; HFA: 44-220 mcg twice daily). Intranasal: 2 sprays (50 mcg/spray) per nostril once daily (total 200 mcg/day). Topical: Apply thin layer to affected area 1-2 times daily.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
None Documented
None Documented
Clinical Note
moderateFluticasone propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin."
Clinical Note
moderateFluticasone propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin."
Clinical Note
moderateFluticasone propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 7.8 hours after intravenous administration; extends to 10-14 hours following intranasal or inhaled routes due to slow absorption from the lung/nasal mucosa.
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Primarily hepatic metabolism via CYP3A4 to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal elimination accounts for >90% of metabolites.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid
Fluticasone propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin."